cnm-au8
cnm-au8: developed by 1 company · 1 clinical trial tracked · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Clene Inc. (CLNN) | Phase 2 |
Clinical Trials (1)
Two Intermediate Expanded Access Protocols for Amyotrophic Lateral Sclerosis With CNM-Au8. CNMAu8.EAP01 and CNM.EAP02
FDA Decisions
FDA_MeetingAdditional biomarker data supporting a potential new drug application (NDA) filing for an upcoming in-person meeting with the FDA.(CLNN)
Frequently asked questions
Who is developing cnm-au8?
cnm-au8 is being developed by Clene Inc..
How many clinical trials involve cnm-au8?
BioSniper tracks 1 clinical trial involving cnm-au8.
What is cnm-au8's latest FDA decision?
The most recent tracked FDA decision for cnm-au8 is FDA_Meeting for Additional biomarker data supporting a potential new drug application (NDA) filing for an upcoming in-person meeting with the FDA..
Get deeper analysis on cnm-au8
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis